...
首页> 外文期刊>Clinical investigation >Korlym~(TM) approved by the US FDA for hyperglycemic control in patients with endogenous Cushing's syndrome
【24h】

Korlym~(TM) approved by the US FDA for hyperglycemic control in patients with endogenous Cushing's syndrome

机译:美国FDA批准的Korlym〜(TM)用于内源性库欣综合征患者的高血糖控制

获取原文
获取原文并翻译 | 示例
           

摘要

The US FDA has recently approved the use of Koriym~(TM), a cortisol receptor blocker, for the control of blood sugar levels in certain adults with endogenous Cushing's syndrome. This subset of patients are characterized by Type 2 diabetes or glucose intolerance and fail to respond to, or are not candidates for, surgery. Endogenous Cushing's syndrome is defined by an overproduction of cortisol and thus this new therapeutic prevents the unwanted effects of this steroid hormone.
机译:美国食品和药物管理局最近批准了使用皮质醇受体阻滞剂Koriym〜(TM)来控制某些患有内源性库欣综合症的成年人的血糖水平。这部分患者的特征是2型糖尿病或葡萄糖耐量异常,对手术无反应或不适合手术。内源性库欣综合症的定义是皮质醇的过量生产,因此这种新的治疗方法可防止这种类固醇激素的不良作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号